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Background.  Acute bacterial meningitis remains a major cause of childhood mortality in sub-Saharan Africa. We document find-
ings from hospital-based sentinel surveillance of bacterial meningitis among children <5 years of age in The Gambia, from 2010 to 2016.
Methods. Cerebrospinal fluid (CSF) was collected from children admitted to the Edward Francis Small Teaching Hospital with 
suspected meningitis. Identification of Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), and 
Haemophilus influenzae was performed by microbiological culture and/or polymerase chain reaction where possible. Whole genome 
sequencing was performed on pneumococcal isolates.
Results. A total of 438 children were admitted with suspected meningitis during the surveillance period. The median age of the 
patients was 13 (interquartile range, 3–30) months. Bacterial meningitis was confirmed in 21.4% (69/323) of all CSF samples ana-
lyzed. Pneumococcus, meningococcus, and H. influenzae accounted for 52.2%, 31.9%, and 16.0% of confirmed cases, respectively. 
There was a significant reduction of pneumococcal conjugate vaccine (PCV) serotypes, from 44.4% in 2011 to 0.0% in 2014, 5 years 
after PCV implementation. The majority of serotyped meningococcus and H. influenzae belonged to meningococcus serogroup W 
(45.5%) and H. influenzae type b (54.5%), respectively. Meningitis pathogens were more frequently isolated during the dry dusty 
season of the year. Reduced susceptibility to tetracycline, trimethoprim-sulfamethoxazole, and chloramphenicol was observed. No 
resistance to penicillin was found.
conclusions. The proportion of meningitis cases due to pneumococcus declined in the post-PCV era. However, the persistence 
of vaccine-preventable meningitis in children aged <5 years is a major concern and demonstrates the need for sustained high-quality 
surveillance.
Keywords. pediatric bacterial meningitis; Streptococcus pneumoniae; Haemophilus influenzae; Neisseria meningitidis; pneumo-
coccal conjugate vaccines.
Bacterial meningitis is associated with very high fatality, with 
reported annual mortality incidence in developing countries 
of 98 per 100  000 in children aged <1  year [1, 2]. Outbreaks 
of epidemic meningitis are particularly frequent in the African 
meningitis belt, a region that extends from Senegal in the 
west, to Ethiopia and Eritrea in the east [3–6]. Predominant 
bacterial causes of meningitis include Neisseria meningitidis 
(meningococcus), Streptococcus pneumoniae (pneumococcus), 
and Haemophilus influenzae type b (Hib) in the pre–Hib vac-
cine era [1, 5, 7, 8].
Immunization against pneumococcus, meningococcus, and 
Hib is one of the proven ways of reducing morbidity and mortality 
of childhood bacterial meningitis [8, 9]. To this end, initiatives 
such as Gavi, the Vaccine Alliance and the Meningitis Vaccine 
Project have led to the accelerated introduction of pneumococcal, 
Hib, and meningococcal conjugate vaccines in several African 
countries during the last 10–15 years. In The Gambia, Hib vac-
cine was introduced into the routine immunization schedule for 
children in 1997 as a primary 3-dose course at 2, 3, and 4 months 
with no booster. Likewise, conjugate vaccine against pneumo-
coccus was introduced in 2009 without a catch-up in a 3  +  0 
schedule, with doses given at 2, 3, and 4 months. Coverage rates 
for pneumococcal and Hib conjugate vaccines remained high 
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(>95%) throughout the surveillance period. Meningococcus vac-
cination campaigns targeting meningococcus serogroup A were 
conducted in 2013 for individuals aged 1–29  years. However, 
monitoring impact of new vaccine efficacy is reliant on robust 
and high-quality surveillance data, which are lacking in many 
low-income countries including The Gambia.
We have conducted analysis to describe the epidemiology 
and etiology of suspected meningitis among children aged 
<5 years in The Gambia between 2010 and 2016.
METHODS
Study Area and Design
Hospital-based sentinel surveillance of bacterial meningitis 
among children <5  years of age is ongoing at the Edward 
Francis Small Teaching Hospital (EFSTH) situated in Banjul, 
the capital city of The Gambia. EFSTH is the only tertiary care 
and referral facility in the country and receives patients from 
all health facilities nationwide. The population of The Gambia 
is estimated as 1.859 million [10]. The prevalence of human 
immunodeficiency virus has remained relatively low, at 1.8% 
(95% CI: 1.4%–3.3%), with predominance in urban rather than 
rural populations [11]. The climate is subtropical with distinct 
dry and rainy seasons. The harmattan (hot and dry winds) lasts 
from November until the onset of the rains in mid-May.
Patients
All suspected cases of meningitis admitted at the EFSTH pedi-
atric ward between 2010 and 2016 underwent a lumbar punc-
ture as part of routine diagnostic procedures. A  suspected 
meningitis case was defined as sudden onset of fever (>38°C 
axillary or >38.5°C rectal temperature), with a combination of 
any of the following clinical symptoms: altered consciousness, 
stiff neck, sensitivity to light, and bulging of the fontanelle if 
the child is <1 year old; a confirmed case was defined as any 
suspected meningitis case that is laboratory-confirmed by cul-
turing or identifying (ie, by polymerase chain reaction [PCR]) 
a bacterial pathogen (H. influenzae, pneumococcus, or menin-
gococcus) in cerebrospinal fluid (CSF) or blood in a child with 
a clinical syndrome consistent with bacterial meningitis [12].
Ethical Review
Pediatric bacterial meningitis surveillance is part of routine 
surveillance for invasive bacterial vaccine-preventable dis-
eases. The standard operating procedures and protocols were 
approved by the Joint Ethics Committee of The Gambia gov-
ernment/Medical Research Council Unit The Gambia at the 
London School of Hygiene and Tropical Medicine (MRCG). 
Ethical approval was not a requirement in The Gambia for rou-
tine meningitis surveillance, including drug susceptibility testing 
of collected isolates, as this is approved within the routine diag-
nostic algorithm at the Ministry of Health. However, informed 
consent was sought from the parents or guardians of the surveil-
lance participants. Additionally, the surveillance received over-
arching ethical approval (SCC1188) by the joint Medical Research 
Council/The Gambia government ethics board that allowed the 
analysis of collected West African isolates at MRCG.
Bacteriologic Analysis of CSF Samples
Gram stain and rapid diagnostic tests for presumptive identifica-
tion of pneumococcus, meningococcus, and H.  influenzae were 
performed at the microbiology laboratories of the EFSTH sentinel 
site. In brief, a portion of the CSF specimen was centrifuged at 
10 000 rpm for 10 minutes. Smears were prepared from the sed-
iment for Gram stain following the WHO protocol [13]. Latex 
agglutination was performed from the CSF supernatant using 
Pastorex meningitis kit (Bio-Rad) for detecting Hib, pneumo-
coccus, and meningococcus groups A, B, C, W, and Y antigens 
following the manufacturer’s instructions. Additionally, 0.5 mL of 
the uncentrifuged CSF was used to test for the presence of pneu-
mococcus antigen using the BINAX NOW kit (Alere) when avail-
able, and white blood cell (WBC) count was carried out with the 
aid of an improved Neubauer counting chamber. CSF protein and 
glucose were analyzed using the trichloroacetic acid turbid metric 
[14] and glucose oxidase [15] methods, respectively.
For culture, a loopful of the CSF sediment was streaked on 
Columbia blood agar (BA) and chocolate agar (CA), each enriched 
with 5% sheep blood. Following overnight incubation, the CA 
and BA plates were examined for characteristic growth of pneu-
mococcus, meningococcus, H.  influenzae, and other pathogens. 
Suspected pneumococcal isolates were confirmed by optochin test 
(5 μg optochin disk; Oxoid). All suspected H. influenzae and me-
ningococcal isolates were subjected to biochemical confirmation 
using analytical profile index (API NH, bioMérieux). Confirmed 
pneumococcal isolates were serotyped by the latex agglutination 
technique as described elsewhere [16]. Meningococcus sero-
groups were confirmed by slide latex agglutination serogrouping 
using Pastorex (Bio-Rad). Haemophilus influenzae serotyping 
was performed by slide agglutination using antisera for serotypes 
a through f (Murex Biotech). Antibiotic susceptibility tests were 
performed by the disk and Etest diffusion methods for commonly 
prescribed antibiotics in the subregion, according to Clinical and 
Laboratory Standards Institute guidelines [17]. All confirmed iso-
lates were stored in 16% glycerol broths for further testing at the 
WHO regional reference laboratory (RRL).
Real-time PCR Detection and Serotyping of Pathogens
Up to 1000  μL of each CSF specimen was transported to the 
WHO RRL for confirmatory testing by real-time PCR. Species-
specific PCR assays for detection of pneumococcus, meningo-
coccus, and H. influenzae were conducted as described elsewhere 
[5]. RNAse P gene assay was performed on all CSF specimens to 
confirm that samples were of human origin and to monitor the 
efficiency of amplification. The amplification cycle involved an 
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initial denaturation step at 95°C for 10 minutes, followed by 45 
cycles of 95°C for 15 seconds and 60°C for 1 minute. Positivity 
for each of the targets was deduced using cycle threshold (Ct) 
values, and Ct values of ≤36 were considered positive.
Serogroup- and Serotype-specific Quantitative PCR Assays
Meningococcal serogrouping and H. influenzae serotyping were 
performed as previously described [18]. Targets for the men-
tioned pathogens included sacB, synD, synE, synG, xcbB, and 
synF genes for serogroups A, B, C, W, X, and Y, respectively. For 
H. influenzae, the following genes were screened for serotyping: 
acsB (type a), bcsB (Hib), ccsD (type c), dscE (type d), ecsH (type 
e), and bexD (type f). Ct values of ≤36 were considered positive.
Streptococcus pneumoniae Serotyping
In preparation for nucleic acid extraction for pneumococcal 
serotyping, 200 µL of CSF was added to 50 µL of TE buffer con-
taining 0.08 g/mL of lysozyme (Sigma, L-6876) and 150 U/mL 
of mutanolysin (Sigma, M-9901), and the mixture was incubated 
for 1 hour at 37°C. The remaining extraction procedures followed 
the Qiagen DNA Mini kit manufacturer’s instructions. Purified 
DNA extracts were subjected to sequential triplex quantita-
tive PCR (qPCR) assay for detecting 21 pneumococcal capsular 
serotypes for the African scheme as previously described [19]. 
Nontypeable pneumococci with Ct values ≤32 by qPCR were fur-
ther subjected to conventional multiplex serotyping PCR assays.
Whole Genome Sequencing
Whole genome sequencing (WGS) was performed at the 
Sanger institute on an Illumina Hiseq as previously described 
[20]. Sequencing reads were mapped on the pneumococcus 
American Type Culture Collection (ATCC) 700669 reference 
genome. The phylogeny of the tree was reconstructed from var-
iable sites using RAxML [21] and visualized in iTOL [22].
RESULTS
Patient Population and Characteristics
A total of 438 suspected meningitis cases were reported at 
EFSTH between 2010 and 2016. The demographic and clinical 
characteristics of the children with suspected meningitis are 
shown in Table 1. The median age of the patients was 13 (inter-
quartile range, 3–30) months. Almost two-thirds of the patients 
were male and two-fifths were aged <1  year with a mortality 
rate of 13.9% (61/438). More than half of the patients had CSF 
with clear appearance as well as with WBC counts (67.4%) of 
≤10 cells/μL. Nearly all (394/438) of the cases did not have a 
known clinical diagnosis reported.
Bacterial Identity and Serotypes
Overall, 98.5% (323/328) of CSF specimens were tested by rapid 
antigen tests, culture, and PCR assays (Figure 1). A  fifth of 
the CSF specimens tested (69/323) had laboratory-confirmed 
bacterial meningitis. Pneumococcus was the major pathogen, 
accounting for 52.2% (36/69) of all confirmed cases, followed 
by meningococcus (31.9% [22/69]) and H.  influenzae (16.0% 
[11/69]) (Figure 2). Prior to 2014, pneumococcal serotypes 1, 5, 
and 6A/6B were the most common pathogens among confirmed 
cases. No cases of pneumococcal meningitis were found during 
2015 and 2016, the last 2 years of the surveillance (Figure 2).
Almost half (10/22) of meningococcal cases belonged to me-
ningococcus serogroup W, and Hib accounted for 54.5% (6/11) 
of all H. influenzae serotypes. Meningitis pathogens were more 
frequently detected during the dry season of January to June 
compared to the wet season (Figure 3).
Genotypes and Resistance Patterns
The EFSTH sentinel site sent a total of 41 pneumococcal isolates 
to the WHO RRL for confirmation, serotyping, antibiogram, and 
molecular characterization during the surveillance period. These 
isolates were primarily from CSF specimens from suspected cases 
of meningitis but also included isolates from blood, lung aspirate, 
Table 1. Patient Characteristics of Suspected Bacterial Meningitis 
Cases (N = 438)
Characteristic No. (%)
Age, mo  
 0–11 178 (40.6)
 12–23 82 (18.7)
 24–59 131 (29.9)
 Unknown 47 (10.7)
Sex  
 Male 260 (59.4)
 Female 174 (39.7)
 Unknown 4 (0.9)
Antibiotic use before admission  
 Yes 19 (4.3)
 No 71 (16.2)
 Unknown 348 (79.5)
Outcome  
 Discharged alive 356 (81.3)
 Died 61 (13.9)
 Unknown 21 (4.8)
CSF appearance  
 Clear 242 (55.3)
 Turbidity 58 (13.4)
 Xanthochromic 20 (4.6)
 Bloodstained 51 (11.6)
 Unknown 67 (15.3)
WBC count, cells/μL  
 0 3 (0.68)
 ≤10 295 (67.4)
 >10 to 100 40 (9.1)
 >100 22 (5.0)
 Unknown/not done 78 (17.8)
Case type  
 Suspected meningitis 369 (84.2)
 Confirmed meningitis 69 (15.8)
Abbreviations: CSF, cerebrospinal fluid; WBC, white blood cell.
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and pus for reference. WGS analysis of the pneumococcal iso-
lates revealed 3 major clades (Figure 4): clade 1, 19F; clade 2, 19F 
and serotype 1; clade 3, all other serotypes including some 19F. 
Additionally, isolates belonging to the same serotype clustered 
together, particularly the predominant invasive serotypes in The 
Gambia (serotypes 1, 5, and 14). However, serotype 19F appeared 
in all the 3 clades, especially ST10810, which clustered with se-
rotype 14 ST63. High susceptibility to penicillin, cefotaxime, 
and erythromycin was noted. The only erythromycin-resistant 
isolate (minimum inhibitory concentration = 125 µg/mL) was a 
serotype 35B (nonvaccine serotype). Reduced susceptibility was 
noted to tetracycline, co-trimoxazole, and to a lesser extent, chlo-
ramphenicol. Compared to the pneumococcal serotype 1 ST3081 
isolates, ST618 isolates were more resistant to trimethoprim-
sulfamethoxazole (16% [1/6] vs 57% [4/7], respectively).
DISCUSSION
We report hospital-based sentinel surveillance data on the eti-
ology and trends of vaccine-preventable bacterial meningitis 
among children <5 years old in The Gambia from 2010 through 
2016. Pneumococcus was the predominant etiologic agent in 
confirmed meningitis cases. Pneumococcal vaccine serotypes 
decreased, whereas the proportion of nonvaccine types in-
creased during the surveillance period. Hib remains a cause of 
bacterial meningitis among young children despite the wide-
spread use of Hib conjugate vaccine.
The widespread use of PCVs has been shown to markedly re-
duce carriage of pneumococcal vaccine serotypes among both 
vaccinated and unvaccinated individuals [23–26]. The 13-valent 
pneumococcal conjugate vaccine (PCV13) was introduced into 
The Gambia’s Expanded Programme on Immunization in 2011. 
Recently, a population-based study of invasive pneumococcal 
disease conducted in the Upper River Region of The Gambia 
showed remarkable public health successes of PCVs associ-
ated with a reduction in invasive pneumococcal diseases [9]. 
Although the number of samples is small, we showed a marked 
reduction in the number of vaccine serotypes and an increase in 
the proportion of nonvaccine serotypes prior 2014. Additionally, 
there was no case of pneumococcal meningitis during the last 
2 years (2015 and 2016) of the surveillance period. The majority 
of CSF samples were collected during the post-PCV13 era.
Figure 1. Summary of cerebrospinal fluid collection and processing for invasive bacterial disease surveillance in The Gambia (2010–2016). Abbreviations: CSF, cerebro-
spinal fluid; PCR, polymerase chain reaction.
Figure 2. Distribution of pathogens associated with pediatric bacterial meningitis in The Gambia (2010–2016). Thirteen-valent pneumococcal conjugate vaccine (PCV13) 
types include serotypes 1, 5, 6A/6B, 14, 19A, and 23F; non-PCV13 serotypes include 8, 11A, and 3 nontypeable pneumococci by real-time polymerase chain reaction.
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Interestingly, our surveillance data showed that H. influenzae 
meningitis was not seasonal, unlike pneumococcus, which 
peaked in the dry season. In contrast, meningococcal menin-
gitis was seasonal and appeared to mimic pneumococcal di-
sease. Meningococcus serogroup W caused several sporadic 
cases of meningitis in The Gambia in the 1990s [27] and was 
also isolated during a serogroup A outbreak in Mali in 1994 [28]. 
Although numbers are small, the predominance of serogroup 
W is consistent with previous reports and suggests continued 
low-level incidence of serogroup W in The Gambia. This finding 
requires a strategy for enhanced surveillance, epidemic detec-
tion and control, and a revision of the vaccination policy in The 
Gambia. Likewise, Hib was among the leading causes of bacte-
rial meningitis in children aged <5 years prior to the introduc-
tion of the Hib conjugate vaccine in The Gambia [29]. Studies 
of the efficacy of the vaccine in The Gambia’s Western Region 
Figure 3. Seasonality of meningitis pathogens in The Gambia (2010–2016).
Figure 4. Phylogeny and antibiogram of pneumococcal isolates associated with childhood bacterial meningitis. Isolates cultured from blood (n = 14); lungs (n = 6), and 
pus (n = 1) are included to contextualize the isolates cultured from cerebrospinal fluid specimens (n = 20). Resistance and intermediate resistance were confirmed by Etest. 
Abbreviations: CHL, chloramphenicol; CSF, cerebrospinal fluid; CTX, cefotaxime; ERY, erythromycin; PEN, penicillin; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline. 
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showed that it was 95% effective in preventing meningitis and 
bloodstream infection, and 100% effective in preventing pneu-
monia [8, 30]. It is therefore concerning that Hib still causes a 
substantial proportion of bacterial meningitis in The Gambia, 
with 6 cases detected throughout the surveillance period.
Finally, our finding of seasonality in meningitis causing 
pathogens agrees with the pattern seen in the meningitis belt, 
with peaks in the first 5 months of the year [5, 31, 32]. A study 
in The Gambia pre-PCV showed regular epidemics of respira-
tory syncytial virus outbreaks mainly during the rainy season 
interrupted by periods of irregularity. These epidemics coin-
cided with an increase in admissions due to respiratory tract 
infections [33]. Meningitis outbreaks occur during the dry and 
dusty harmattan winds that blow between November and May 
across the Sahel. These harmattan winds carry fine fractions of 
particulate matter. Following the introduction of conjugate vac-
cines, the links between dust inhalation, carriage of respiratory 
pathogens including influenza, and respiratory syncytial virus 
need to be investigated further in The Gambia.
A major limitation of the surveillance is the incomplete clin-
ical and demographic data for up to 40% of patients with sus-
pected meningitis who had a lumbar puncture performed. This 
reduced the quality of data available to describe the basic clin-
ical characteristics and etiology of pediatric meningitis cases. 
Additionally, incomplete vaccination records, especially for 
H.  influenzae meningitis cases, hampered our description of 
vaccination failure in these children. Also, it would have been 
very useful to know what percentage of the patients with pneu-
mococcal meningitis had received PCV vaccine. Unfortunately, 
these data were not available for such an analysis.
CONCLUSIONS
Meningitis caused by pneumococcus, meningococcus, and 
H. influenzae remains a major cause of child mortality and mor-
bidity in The Gambia. Enhanced surveillance for monitoring of 
vaccine impact and detection of meningitis is recommended for 
early detection of epidemics. The WHO RRL should continue 
to work with The Gambia sentinel site to strengthen laboratory 
and surveillance capacity that will enhance high-quality data 
capture on bacterial meningitis–causing pathogens.
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